Regeneron's Eylea Faces Challenges, Stock Price Drops

Regeneron Pharmaceuticals is experiencing headwinds with its key drug, Eylea, leading to a decline in share price despite strong overall performance. Investors weigh the potential impact on future sales amidst biosimilar competition and legal challenges.

Date: 05-10-2024

AI Rating: 6

Regeneron Pharmaceuticals has seen an increase in total revenue, with reported figures of $3.55 billion, which is a 12% year-over-year increase. A significant portion of this revenue is derived from its drug Eylea, which generated U.S. sales of $1.53 billion in the second quarter, accounting for 43% of the company’s revenue. This is a modest increase, attributable also to the newly approved higher-dose formulation of Eylea, which saw revenue of $304 million.

However, the company faces considerable challenges primarily due to the competitive landscape affecting Eylea. The introduction of Vabysmo, a competing treatment from Roche, has intensified the pressure on Eylea; moreover, the approval of the biosimilar Pavblu by Amgen poses a potential threat. This situation is exacerbated by a recent court ruling that did not favor Regeneron, allowing Amgen to launch its biosimilar product.

While the current hurdles with Eylea could indicate potential revenue losses, Regeneron’s earnings could benefit from its other major product, Dupixent, which reported a year-over-year revenue growth of 27% to $3.56 billion. This suggests that although Eylea's market position is precarious, Dupixent remains a strong driver for Regeneron’s finances.

Thus, should investors steer clear of Regeneron due to its current setbacks with Eylea? While the situation is indeed challenging, the continued growth prospects of Dupixent, along with Regeneron’s robust pipeline of over 50 programs, could help stabilize the company’s financial future.

Stocks: REGN AMGN RHHBY